-DOCSTART- -X- O
Current -X- _ O
influenza -X- _ O
vaccines -X- _ O
provide -X- _ O
hemagglutinin -X- _ O
strain-specific -X- _ O
protection -X- _ O
, -X- _ O
but -X- _ O
rarely -X- _ O
provide -X- _ O
cross-protection -X- _ O
against -X- _ O
divergent -X- _ O
strains. -X- _ O
It -X- _ O
is -X- _ O
, -X- _ O
therefore -X- _ O
, -X- _ O
particularly -X- _ O
important -X- _ O
to -X- _ O
develop -X- _ O
a -X- _ O
universal -X- _ O
vaccine -X- _ O
against -X- _ O
conserved -X- _ O
proteins -X- _ O
or -X- _ O
conserved -X- _ O
regions -X- _ O
of -X- _ O
the -X- _ O
virus. -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
we -X- _ O
used -X- _ O
N-terminal -X- _ B-Patient
extracellular -X- _ I-Patient
region -X- _ I-Patient
of -X- _ I-Patient
the -X- _ I-Patient
influenza -X- _ I-Patient
virus -X- _ I-Patient
M2 -X- _ I-Patient
protein -X- _ I-Patient
( -X- _ I-Patient
M2e -X- _ I-Patient
) -X- _ I-Patient
as -X- _ O
the -X- _ O
target -X- _ O
antigen -X- _ O
and -X- _ O
constructed -X- _ O
two -X- _ O
optimized -X- _ B-Intervention
M2e -X- _ I-Intervention
DNA -X- _ I-Intervention
vaccines -X- _ I-Intervention
( -X- _ I-Intervention
p-tPA-p3M2e -X- _ I-Intervention
and -X- _ I-Intervention
p-p3M2e -X- _ I-Intervention
) -X- _ I-Intervention
with -X- _ O
increased -X- _ O
antigenic -X- _ O
epitope -X- _ O
density -X- _ O
and -X- _ O
enhanced -X- _ O
antigen -X- _ O
secretion. -X- _ O
Both -X- _ O
vaccines -X- _ O
induced -X- _ B-Outcome
high -X- _ I-Outcome
M2e-specific -X- _ I-Outcome
humoral -X- _ I-Outcome
and -X- _ I-Outcome
cellular -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
vaccinated -X- _ I-Outcome
mice. -X- _ I-Outcome
These -X- _ I-Outcome
two -X- _ I-Outcome
vaccines -X- _ I-Outcome
also -X- _ I-Outcome
conferred -X- _ I-Outcome
protection -X- _ I-Outcome
against -X- _ I-Outcome
a -X- _ I-Outcome
lethal -X- _ I-Outcome
infection -X- _ I-Outcome
of -X- _ I-Outcome
homo-subtypic -X- _ I-Outcome
H1N1 -X- _ I-Outcome
virus -X- _ I-Outcome
, -X- _ I-Outcome
with -X- _ I-Outcome
p-tPA-p3M2e -X- _ I-Outcome
being -X- _ I-Outcome
the -X- _ I-Outcome
most -X- _ I-Outcome
effective. -X- _ I-Outcome
In -X- _ O
addition -X- _ O
, -X- _ O
p-tPA-p3M2e -X- _ B-Outcome
also -X- _ I-Outcome
showed -X- _ I-Outcome
cross-protection -X- _ I-Outcome
against -X- _ I-Outcome
different -X- _ I-Outcome
subtypes -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
influenza -X- _ I-Outcome
virus -X- _ I-Outcome
( -X- _ I-Outcome
H9N2 -X- _ I-Outcome
, -X- _ I-Outcome
H6N6 -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
H10N8 -X- _ I-Outcome
) -X- _ I-Outcome
at -X- _ I-Outcome
varying -X- _ I-Outcome
rates -X- _ I-Outcome
( -X- _ I-Outcome
80 -X- _ I-Outcome
% -X- _ I-Outcome
, -X- _ I-Outcome
40 -X- _ I-Outcome
% -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
20 -X- _ I-Outcome
% -X- _ I-Outcome
, -X- _ I-Outcome
respectively -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
After -X- _ O
passive -X- _ O
immunization -X- _ O
, -X- _ O
M2e -X- _ O
DNA -X- _ O
vaccine-induced -X- _ O
antibodies -X- _ O
in -X- _ O
the -X- _ O
sera -X- _ O
provided -X- _ O
complete -X- _ O
protection -X- _ O
against -X- _ O
homologous -X- _ O
virus -X- _ O
challenge. -X- _ O
An -X- _ O
analysis -X- _ O
of -X- _ O
the -X- _ O
mechanism -X- _ O
underlying -X- _ O
this -X- _ O
immunization-mediated -X- _ O
protection -X- _ O
indicates -X- _ O
that -X- _ O
M2e-specific -X- _ O
IgG -X- _ O
and -X- _ O
T-cell -X- _ O
immune -X- _ O
responses -X- _ O
may -X- _ O
play -X- _ O
critical -X- _ O
roles -X- _ O
in -X- _ O
the -X- _ O
prevention -X- _ O
of -X- _ O
infection -X- _ O
and -X- _ O
viral -X- _ O
clearance. -X- _ O
Taken -X- _ O
together -X- _ O
, -X- _ O
our -X- _ O
results -X- _ O
indicate -X- _ O
that -X- _ O
this -X- _ O
optimized -X- _ B-Outcome
M2e -X- _ I-Outcome
DNA -X- _ I-Outcome
vaccine -X- _ I-Outcome
is -X- _ I-Outcome
a -X- _ I-Outcome
promising -X- _ I-Outcome
candidate -X- _ I-Outcome
for -X- _ I-Outcome
the -X- _ I-Outcome
development -X- _ I-Outcome
of -X- _ I-Outcome
a -X- _ I-Outcome
universal -X- _ I-Outcome
, -X- _ I-Outcome
broad-spectrum -X- _ I-Outcome
influenza -X- _ I-Outcome
virus -X- _ I-Outcome
vaccine -X- _ I-Outcome
. -X- _ O

